Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis.

ABSTRACT: Few controlled trials of disease-modifying therapies (DMTs) have been conducted on the pediatric-onset multiple sclerosis (PoMS) population, leading to extensive off-label use of therapies approved only for adults. This highlights the need for real-world evidence to guide clinical practice. Clinical registries can offer high-quality data, but limitations such as missing and erroneous information must be considered. This validation study compared Swedish Multiple Sclerosis registry data from 122 PoMS patients to medical records. Generally (≥89%), data were confirmed. However, missing data exceeded 30% for rituximab infusions, magnetic resonance imaging, and relapses. Overall, the registry provides valid, real-world data on DMT use in PoMS.

SUBMITTER: Sandesjo F 

PROVIDER: S-EPMC11808745 | biostudies-literature | 2025 Jan-Mar

REPOSITORIES: biostudies-literature